Regulators push openness agenda on raw trial data…and EUPATI issues call for examples of educational materials on medicines development

Yes, that is a long headline is it not?  PharmaTimes and others cover a paper in PloS Medicine authored by a number of medicines regulators including the European Medicines Agency (EMA), calling for openness in raw trial data. The three pronged approach they suggest looks like a good basis for discussion.  It would be interesting… Read More Regulators push openness agenda on raw trial data…and EUPATI issues call for examples of educational materials on medicines development

EU initiative to boost information for patients on medicines development

The EU economy might be splintering apart.  But, meanwhile, a number of patient/public/private organisations are ‘euro-zoning’ in on the task of providing better information for patients on medicines development. The new initiative – which was launched on 1st February – is called the European Patients Academy on Therapeutic Innovation  or EUPATI for short. Thank goodness they did… Read More EU initiative to boost information for patients on medicines development